Emergency anthrax drug trial set to launch if outbreak strikes
NCT ID NCT03569553
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test a medicine called AIGIV for people who have breathed in anthrax germs during a large-scale emergency. The goal is to see if the drug helps more people survive and to check for side effects. The study will only start if a major anthrax event happens, and it will include up to 100 patients.
Why investors are watching
Emergent BioSolutions is testing AIGIV, an antibody treatment for inhalational anthrax, in a field study that would only run during a major anthrax exposure event. For a small-cap company with a focus on biodefense, this trial tests whether its product works in a real-world emergency, which could affect its standing with government buyers. The outcome matters because anthrax treatments are a niche market where success depends on regulatory and public health confidence.
If it works: A positive result could strengthen Emergent's position as a supplier of anthrax countermeasures, potentially leading to more government contracts or stockpile orders. It would also validate AIGIV as a useful tool in a public health crisis, which could support future revenue from emergency preparedness programs.
If it fails: The trial may never enroll participants, since it only activates during a major anthrax event, so the company might not get the data it needs. If the study does run and AIGIV shows poor safety or no clear benefit, it could damage the product's credibility and hurt Emergent's biodefense business.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2027
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Inhalational anthrax patients who have received AIGIV.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed or suspected inhalational anthrax linked to an identified broad exposure scenario. * Treatment with AIGIV. * Informed consent/assent (as applicable). Exclusion Criteria: * There are no exclusion criteria for subjects enrolling in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Inhalational anthrax are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.